Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELZ NASDAQ:MAAQ NASDAQ:RNTX NASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$3.44+0.9%$3.02$1.69▼$6.90$8.80M2.06117,300 shs19,777 shsMAAQMana Capital Acquisition$3.63-2.2%$3.93$5.35▼$10.25$29.49MN/A33,075 shs29,985 shsRNTXRein Therapeutics$1.19-9.2%$1.30$1.04▼$4.40$30.53M1.13112,086 shs96,689 shsRVPHReviva Pharmaceuticals$0.45-0.3%$0.45$0.30▼$4.28$30.39M-0.042.04 million shs976,643 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology+0.88%+2.99%+17.81%+56.36%+2.08%MAAQMana Capital Acquisition0.00%-6.68%+5.22%-14.18%+1,072.86%RNTXRein Therapeutics-9.16%-5.56%+2.59%-39.59%+118,999,900.00%RVPHReviva Pharmaceuticals-0.34%-3.17%-0.47%-42.90%-66.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$3.44+0.9%$3.02$1.69▼$6.90$8.80M2.06117,300 shs19,777 shsMAAQMana Capital Acquisition$3.63-2.2%$3.93$5.35▼$10.25$29.49MN/A33,075 shs29,985 shsRNTXRein Therapeutics$1.19-9.2%$1.30$1.04▼$4.40$30.53M1.13112,086 shs96,689 shsRVPHReviva Pharmaceuticals$0.45-0.3%$0.45$0.30▼$4.28$30.39M-0.042.04 million shs976,643 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology+0.88%+2.99%+17.81%+56.36%+2.08%MAAQMana Capital Acquisition0.00%-6.68%+5.22%-14.18%+1,072.86%RNTXRein Therapeutics-9.16%-5.56%+2.59%-39.59%+118,999,900.00%RVPHReviva Pharmaceuticals-0.34%-3.17%-0.47%-42.90%-66.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELZCreative Medical Technology 2.00HoldN/AN/AMAAQMana Capital Acquisition 0.00N/AN/AN/ARNTXRein Therapeutics 2.00HoldN/AN/ARVPHReviva Pharmaceuticals 3.14Buy$5.201,067.49% UpsideCurrent Analyst Ratings BreakdownLatest CELZ, RNTX, MAAQ, and RVPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025RNTXRein TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/18/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00 ➝ $3.008/18/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/15/2025RVPHReviva PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/15/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $2.008/12/2025CELZCreative Medical TechnologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELZCreative Medical Technology$10K887.52N/AN/A$3.63 per share0.95MAAQMana Capital AcquisitionN/AN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/A$0.41 per share2.93$0.43 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELZCreative Medical Technology-$5.49M-$3.18N/AN/AN/AN/A-82.99%-79.49%11/14/2025 (Estimated)MAAQMana Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ARNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/ARVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)Latest CELZ, RNTX, MAAQ, and RVPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/A8/8/2025Q2 2025CELZCreative Medical Technology-$0.63-$0.48+$0.15-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELZCreative Medical TechnologyN/AN/AN/AN/AN/AMAAQMana Capital AcquisitionN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELZCreative Medical TechnologyN/A23.8623.86MAAQMana Capital AcquisitionN/AN/AN/ARNTXRein TherapeuticsN/A0.860.86RVPHReviva PharmaceuticalsN/A0.900.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELZCreative Medical Technology1.42%MAAQMana Capital Acquisition68.44%RNTXRein Therapeutics90.89%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipCELZCreative Medical Technology2.80%MAAQMana Capital AcquisitionN/ARNTXRein Therapeutics5.10%RVPHReviva Pharmaceuticals27.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELZCreative Medical Technology52.58 million2.51 millionNot OptionableMAAQMana Capital Acquisition18.13 millionN/ANot OptionableRNTXRein Therapeutics923.31 million22.12 millionN/ARVPHReviva Pharmaceuticals568.00 million49.52 millionOptionableCELZ, RNTX, MAAQ, and RVPH HeadlinesRecent News About These CompaniesReviva Pharmaceuticals (NASDAQ:RVPH) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD) Critical ReviewSeptember 8 at 2:25 AM | americanbankingnews.comPivotal Therapeutics (OTCMKTS:PVTTF) versus Reviva Pharmaceuticals (NASDAQ:RVPH) Head-To-Head SurveySeptember 1, 2025 | americanbankingnews.comRVPH: There May Be A Faster WayAugust 19, 2025 | finance.yahoo.comReviva Pharmaceuticals Advances Schizophrenia TreatmentAugust 18, 2025 | tipranks.comReviva Pharmaceuticals price target lowered to $3 from $7 at Roth CapitalAugust 18, 2025 | msn.comReviva Narrows Loss 23% in Fiscal Q2August 14, 2025 | aol.comAReviva Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 14, 2025 | globenewswire.comReviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comReviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.comJune 29, 2025 | investing.comReviva Dives on Stock OfferingJune 26, 2025 | baystreet.caReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingJune 26, 2025 | globenewswire.comReviva Pharmaceuticals stock falls after announcing public offeringJune 25, 2025 | za.investing.comReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingJune 25, 2025 | globenewswire.comRVPH: Open Label Extension Results & Key Opinion Leader DiscussionJune 5, 2025 | finance.yahoo.comReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 5, 2025 | globenewswire.comReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaJune 2, 2025 | globenewswire.comReviva to Participate in Upcoming Investor Conferences in May 2025May 20, 2025 | santelog.comSReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comReviva to Participate in the A.G.P. Healthcare Company ShowcaseMay 13, 2025 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)May 4, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELZ, RNTX, MAAQ, and RVPH Company DescriptionsCreative Medical Technology NASDAQ:CELZ$3.44 +0.03 (+0.88%) Closing price 09/10/2025 03:47 PM EasternExtended Trading$3.34 -0.10 (-2.94%) As of 07:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Mana Capital Acquisition NASDAQ:MAAQ$3.63 -0.08 (-2.16%) As of 09/8/2025Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.Rein Therapeutics NASDAQ:RNTX$1.19 -0.12 (-9.16%) As of 09/10/2025 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Reviva Pharmaceuticals NASDAQ:RVPH$0.45 0.00 (-0.34%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$0.46 +0.02 (+3.50%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
